Milestone
Cellzome Inc. of Heidelberg and Cambridge has announced that it has achieved two further milestones in its strategic alliance with GlaxoSmithKline plc. The achievement of these second and third milestones triggers an individual payment for each milestone, but the amounts were not undisclosed.
In September 2008 Cellzome and GlaxoSmithKline signed a worldwide alliance under which Cellzome’s drug discovery and development capabilities and its proprietary Kinobeads technology are used to identify, develop and market novel, kinase-targeted therapeutics to treat inflammatory diseases. GSK has exclusive options to license drug candidates from Cellzome’s kinase programmes against seven targets. Under the deal Cellzome is responsible for developing these programmes to clinical proof-of-concept, unless GSK elects to exercise its option earlier. The first milestone in the alliance was announced in December 2008.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
